Actor portrayals.
Actor portrayal.

Clinical Data

Attruby was proven to make an impact on survival, hospitalizations, and quality of life1,2*

*Defined as health-related quality of life and functional capacity.1

Secondary Endpoints
Primary Endpoint
Survival
Hospitalizations
KCCQ-OS/6MWD
Serum TTR
NT-proBNP
Select Endpoint
Primary Endpoint icon

Reduce combined ACM and CVH frequency.
Keep life in motion.

Attruby significantly reduced the combination of ACM and CVH at Month 301,2

The primary composite endpoint at Month 30 vs placebo included:

All cause

All-cause
mortality

CV-related hospitalization CV-related hospitalization

Cumulative frequency of CV-related hospitalizations

P=0.018, assessed using the
stratified F-S test info
See ATTRibute-CM Study Design See ATTRibute-CM
Study Design
Calendar

OLE Results up to
42 months3

More on OLE Study Design

Learn more about the ATTRibute-CM
clinical trial info and the primary hierarchical
composite endpoint info  .

It's not just the impact. It's when you see it.

Attruby showed an early observable difference starting at Month 3
that diverged through 30 months1

Time to First Event (ACM or CVH)1
Table Table Table Table
Table Table

Number needed to treat to
avoid a
death or first CVH
over 2.5 years1: 7

7 Patients
More on Variant Subgroup
IN A POST HOC ANALYSIS
42
% RRR
IN THE COMPOSITE OF ACM
AND RECURRENT CVH4†
THROUGH 30 MONTHS
PDF Guide

See results across patients with
wild-type and variant ATTR-CM

Download
image image Actor portrayals.

†RRR was calculated using the negative binomial regression model. The total number of events for Attruby compared with placebo (2:1 randomized) was
79 vs 52 for ACM, respectively, and 182 vs 170 for CVH, respectively.4

6MWD=6-minute walk distance; ACM=all-cause mortality; ATTR-CM=transthyretin amyloid cardiomyopathy; ATTRv=variant transthyretin-mediated amyloidosis;
ATTRwt=wild-type transthyretin-mediated amyloidosis; CFB=change from baseline; CV=cardiovascular; CVH=cardiovascular-related hospitalization; F-S
test=Finkelstein-Schoenfeld test; HR=hazard ratio; NT-proBNP=N-terminal pro–B-type natriuretic peptide; OLE=open-label extension;
RRR=relative risk reduction.

References: 1. Attruby. Prescribing information. BridgeBio Pharma, Inc.; 2024. 2. Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132-142. doi:10.1056/NEJMoa2305434 3. Judge DP, Gillmore JD, Alexander KM, et al. Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial. Circulation. 2025;151(9):601-611. doi:10.1161/ CIRCULATIONAHA.124.072771 4. Judge DP, Alexander KM, Cappelli F, et al. Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2025;85(10):1003-1014. doi:10.1016/j.jacc.2024.11.042 5. Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy [study protocol]. N Engl J Med. 2024;390(2):132-142. doi:10.1056/NEJMoa2305434 6. Alexander KM, Davis MK, Akinboboye O, et al. Efficacy of acoramidis in wild-type and variant transthyretin amyloid cardiomyopathy: results from ATTRibute-CM and Its open-label extension. JAMA Cardiol. Published online November 8, 2025. doi:10.1001/jamacardio.2025.4477 7. Judge DP, Gillmore JD, Alexander KM, et al. Long- term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial. Circulation. 2025;151(9) (suppl 1):1-4. doi:10.1161/CIRCULATIONAHA.124.072771 8. Data on file. BridgeBio Pharma, Inc.; 2024-2025.

Secondary Endpoints
Primary Endpoint
Survival
Hospitalizations
KCCQ-OS/6MWD
Serum TTR
NT-proBNP
Select an endpoint for more
Attruby data
Primary Endpoint icon

Attruby was studied in a contemporary
ATTR-CM population that reflects recent
approaches in diagnosis and care

Attruby was studied
in a contemporary
population that reflects
recent approaches in
diagnosis and care

See Study Design
The F-S test is a statistical method based on the principle that each subject is compared to every other subject in each stratum in a pair-wise, hierarchical manner. ACM and cumulative CVH were considered to be the most clinically important components within the hierarchical endpoint and were appropriately the first and second components of
the hierarchy.

The F-S test results in a P value relating to the statistical significance of the difference noted between treatment and placebo groups but does not provide a magnitude of benefit. The magnitude of benefit is shown by the win ratio.5 The 4-step primary hierarchical composite endpoint evaluated in the ATTRibute-CM clinical trial included ACM, CVH, change from baseline in NT-proBNP, and change from baseline in 6MWD (assessed using the stratified F-S test).

The Attruby USPI describes the primary endpoint as a 2-part composite that includes ACM and cumulative frequency of CVH over 30 months.1,2 ATTRibute-CM was a phase 3, randomized (2:1), double-blind, placebo-controlled study that assessed the efficacy (N=611) and safety (N=632) of Attruby in adults with hereditary or wild-type cardiac amyloidosis over 30 months.1,2 The win ratio was calculated to aid the interpretation of results from the F-S scoring algorithm to show the magnitude of effect between
Attruby and placebo. The stratified nonmatched win ratio method allocated all treated and placebo pairs within each stratum in the same hierarchical structure as the
F-S test.

In ATTRibute-CM, Attruby achieved a statistically significant
1.8 win ratio in the 4-component composite.2,5

Indication and Important safety information

INDICATION

Attruby® (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation.

Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

Laboratory Tests
Mean increase in serum creatinine of 0.2 and 0.0 mg/dL and a mean decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m2 was observed in the adults with ATTR-CM treated with Attruby versus placebo, respectively, at Day 28 and then stabilized. These changes were reversible after treatment discontinuation.

Use in Specific Populations

Pregnancy & Lactation: There are no data on the use of Attruby in pregnant women. Animal data have not shown developmental risk associated with the use of Attruby in pregnancy. There are no available data on the presence of Attruby in either human or animal milk or the effects of the drug on the breastfed infant or maternal milk production.

Please see Full Prescribing Information including Patient Information.

INDICATION AND IMPORTANT
SAFETY INFORMATION

INDICATION

Attruby® (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation.

Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

Laboratory Tests
Mean increase in serum creatinine of 0.2 and 0.0 mg/dL and a mean decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m2 was observed in the adults with ATTR-CM treated with Attruby versus placebo, respectively, at Day 28 and then stabilized. These changes were reversible after treatment discontinuation.

Use in Specific Populations

Pregnancy & Lactation: There are no data on the use of Attruby in pregnant women. Animal data have not shown developmental risk associated with the use of Attruby in pregnancy. There are no available data on the presence of Attruby in either human or animal milk or the effects of the drug on the breastfed infant or maternal milk production.

Please see Full Prescribing Information including Patient Information.